Blog

Blueprint Medicines and PatientCrossroads Launch Registry for Mastocytosis Patients to Increase Understanding of Disease and Speed Therapeutic Development

Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, and PatientCrossroads, a pioneer in spearheading the adoption of patient-entered disease registries, today announced the launch of Mast Cell Connect, a patient registry to advance the understanding of mastocytosis and help speed the development of new therapies. Blueprint Medicines, which is developing a treatment for patients with systemic mastocytosis, is sponsoring the registry. PatientCrossroads’ robust platform will be used to host and manage the registry, including patient privacy, data collection and access.

 

Read More

Mersana Therapeutics to Present Poster at the 2015 San Antonio Breast Cancer Symposium

Mersana Therapeutics, Inc. today announced that it will present a poster at the 2015 San Antonio Breast Cancer Symposium, taking place December 8-12, 2015, at the Henry B. Gonzalez Convention Center in San Antonio, TX.
XMT-1522, Mersana’s lead product candidate, is a novel HER2-targeting therapy based on Mersana’s Fleximer® immunoconjugate technology that carries an average of 15 proprietary auristatin payload molecules.
The annual Symposium provides a forum for sharing new breast cancer insights and data. The meeting is sponsored by the Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research and Baylor College of Medicine.

TraceLink, Roche and SPI Win GS1 Brazil Automation Award for RDC 54 Compliance Pilot

TraceLink Inc., the world’s largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced that the company has been awarded the 2015 GS1 Brazil Automation Award for its partnership with Roche and SPI in developing an ANVISA pilot solution to meet the Brazil RDC 54 track and trace regulation. TraceLink, Roche and SPI were recognized for their innovation and entrepreneurship in creating practical solutions based on industry standards to meet key business challenges at the GS1 Brazil award ceremony on November 11th in Sao Paulo Brazil.

 

Read More

ViewRay® to Present at the LD Micro “Main Event” Microcap Conference

ViewRay, Inc. (OTCQB:VRAY) announced that the Company will present at the 8th Annual LD Micro “Main Event” Microcap Conference in Los Angeles, CA.

The Company will be available for 1×1 meetings at the conference. Please contactviewray@theruthgroup.com for more information. The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 210 companies. An audio webcast of the Company’s presentation will be available online at www.viewray.com. A replay of the presentation will be available for 90 days.

ViewRay, Inc. of Cleveland, Ohio, is a medical device company that develops advanced radiation therapy technology for the treatment of cancer. The MRIdian® system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient’s anatomy.

 

Read More

Proteostasis Therapeutics, Inc. Demonstrates Therapeutic Potential of a Proprietary Triple Combination Therapy for the Treatment of Cystic Fibrosis that Restores Activity of Mutant F508del CFTR Protein to 80% of Normal

Proteostasis Therapeutics, Inc. (PTI), a company developing small molecule therapeutics to treat diseases caused by defects in protein processing, announced today the expansion of its cystic fibrosis (CF) drug candidate pipeline to include the addition of a novel triple combination therapy of PTI’s own CFTR amplifiers, correctors and potentiators. PTI’s testing has shown that a triple combination comprising a proprietary corrector and potentiator, currently in late lead optimization stage, and one of PTI’s CFTR amplifiers, can restore the activity of mutant F508del CFTR protein to 80% of normal activity in Ussing chamber assays.

 

Read More

Aclaris Therapeutics Reports Third Quarter 2015 Financial Results

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2015.

“We are very pleased with the completion of our initial public offering in early October, including the exercise in full of the underwriters’ option to purchase additional shares. The additional capital will provide Aclaris the ability to advance our proprietary pipeline, including our lead drug candidate A-101 for seborrheic keratosis, as we execute on our strategy to build a fully integrated dermatology company,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.

 

Read More

PatientPing Announces $9.6M in Funding from Google Ventures, F-Prime Capital, and First Round to Build the First National Care Coordination Network

BOSTON, MA (November 16, 2015) — PatientPing, a company that connects healthcare providers across the country with real-time notifications when patients receive care, announced today that it has raised $9.6M led by Google Ventures and F-Prime Capital (the venture capital funds of FMR LLC, the parent company of Fidelity), with participation from First Round Capital and SV Angel.

Read the full press release here.

Driven by the changing incentives of the Affordable Care Act, providers are compelled to work with one another when they share patients. These new collaborations are bringing together historically disparate and siloed healthcare facilities in regional provider communities that more efficiently deliver high quality care wherever patients go. PatientPing is fueling this transition by providing a critical missing link for providers operating in this new environment: the ability to be notified instantly when a patient is receiving care anywhere – inside or outside of their facility or health system – and the ability to collaborate with providers to ensure the best health outcomes for patients.

Upon joining PatientPing, providers receive “Pings,” real-time notifications, whenever their patients receive care at any facility that is a part of the national PatientPing network. At the facility where patients are getting care, providers receive guidelines that include contact information for others on the patient’s care team, helpful instructions from the care team, and patient visit histories. By sharing this information in real-time, providers can seamlessly coordinate their patient’s care.

Semma Therapeutics Acquires Providence Biotech Company, CytoSolv, Inc.

A Cambridge, Mass., company, Semma Therapeutics, has acquired Providence-based CytoSolv, Inc., which has garnered local support since its founding in 2010 from the Slater Technology Fund and others, Slater announced Monday.

CytoSolv will continue to operate out of its recently expanded Providence location at 117 Chapman St.

No details about acquisition costs were disclosed, but Slater notes that Semma has recently announced $44 million of initial investment led by MPM Capital.

The co-founders of CytoSolv, Dr. Moses Goddard and Christopher Thanos, are now employees of the Cambridge company, according to a prepared statement from the Slater Technology Fund. Goddard is now chief medical officer, and Thanos is vice president of delivery. A principal CytoSolv scientist, Briannan Bintz, will be director of delivery at Semma.

Read More

TraceLink Ranked Number 293 Fastest Growing Company in North America on Deloitte’s 2015 Technology Fast 500(TM)

TraceLink Inc., the world’s largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced that it has been ranked number 293 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. TraceLink, which achieved revenue growth of 236 percent from 2011 to 2014, is one of only 15 software companies from Massachusetts to be ranked on the 2015 Deloitte Technology Fast 500™, and is ranked number seven (7) among the fastest growing software companies headquartered in the state.

 

Read More

Tetraphase Pharmaceuticals to Provide Corporate Update at Stifel 2015 Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation, including an update on its eravacycline development program, at the Stifel 2015 Healthcare Conference on November 17, 2015 at 8:00 a.m. Eastern Time at The New York Palace Hotel in New York City.

Read More